Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Viruses ; 13(4)2021 04 02.
Article in English | MEDLINE | ID: mdl-33918301

ABSTRACT

The outbreak of SARS-CoV-2 developed into a global pandemic affecting millions of people worldwide. Despite one year of intensive research, the current treatment options for SARS-CoV-2 infected people are still limited. Clearly, novel antiviral compounds for the treatment of SARS-CoV-2 infected patients are still urgently needed. Complementary medicine is used along with standard medical treatment and accessible to a vast majority of people worldwide. Natural products with antiviral activity may contribute to improve the overall condition of SARS-CoV-2 infected individuals. In the present study, we investigated the antiviral activity of glycyrrhizin, the primary active ingredient of the licorice root, against SARS-CoV-2. We demonstrated that glycyrrhizin potently inhibits SARS-CoV-2 replication in vitro. Furthermore, we uncovered the underlying mechanism and showed that glycyrrhizin blocks the viral replication by inhibiting the viral main protease Mpro that is essential for viral replication. Our data indicate that the consumption of glycyrrhizin-containing products such as licorice root tea of black licorice may be of great benefit for SARS-CoV-2 infected people. Furthermore, glycyrrhizin is a good candidate for further investigation for clinical use to treat COVID-19 patients.


Subject(s)
Antiviral Agents/pharmacology , Glycyrrhizic Acid/pharmacology , Protease Inhibitors/pharmacology , SARS-CoV-2/drug effects , Virus Replication/drug effects , Animals , COVID-19 , Cell Survival/drug effects , Chlorocebus aethiops , Coronavirus 3C Proteases/drug effects , Glycyrrhiza/chemistry , Humans , Peptide Hydrolases/drug effects , Plant Extracts/pharmacology , Plant Roots/chemistry , Vero Cells
2.
Proc Natl Acad Sci U S A ; 118(13)2021 03 30.
Article in English | MEDLINE | ID: mdl-33723007

ABSTRACT

Preclinical testing of novel therapeutics for chronic hepatitis B (CHB) requires suitable animal models. Equids host homologs of hepatitis C virus (HCV). Because coinfections of hepatitis B virus (HBV) and HCV occur in humans, we screened 2,917 specimens from equids from five continents for HBV. We discovered a distinct HBV species (Equid HBV, EqHBV) in 3.2% of donkeys and zebras by PCR and antibodies against EqHBV in 5.4% of donkeys and zebras. Molecular, histopathological, and biochemical analyses revealed that infection patterns of EqHBV resembled those of HBV in humans, including hepatotropism, moderate liver damage, evolutionary stasis, and potential horizontal virus transmission. Naturally infected donkeys showed chronic infections resembling CHB with high viral loads of up to 2.6 × 109 mean copies per milliliter serum for >6 mo and weak antibody responses. Antibodies against Equid HCV were codetected in 26.5% of donkeys seropositive for EqHBV, corroborating susceptibility to both hepatitis viruses. Deltavirus pseudotypes carrying EqHBV surface proteins were unable to infect human cells via the HBV receptor NTCP (Na+/taurocholate cotransporting polypeptide), suggesting alternative viral entry mechanisms. Both HBV and EqHBV deltavirus pseudotypes infected primary horse hepatocytes in vitro, supporting a broad host range for EqHBV among equids and suggesting that horses might be suitable for EqHBV and HBV infections in vivo. Evolutionary analyses suggested that EqHBV originated in Africa several thousand years ago, commensurate with the domestication of donkeys. In sum, EqHBV naturally infects diverse equids and mimics HBV infection patterns. Equids provide a unique opportunity for preclinical testing of novel therapeutics for CHB and to investigate HBV/HCV interplay upon coinfection.


Subject(s)
Coinfection/veterinary , Equidae/virology , Hepatitis B virus/pathogenicity , Hepatitis B, Chronic/veterinary , Hepatitis C/veterinary , Animals , Antibodies, Viral/isolation & purification , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Cell Line, Tumor , Cells, Cultured , Coinfection/drug therapy , Coinfection/virology , DNA, Viral/isolation & purification , Disease Models, Animal , Drug Evaluation, Preclinical/methods , Female , Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepacivirus/pathogenicity , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Hepatitis B virus/isolation & purification , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Hepatitis C/drug therapy , Hepatitis C/virology , Hepatocytes , Humans , Liver/immunology , Liver/pathology , Liver/virology , Primary Cell Culture , Virus Internalization
3.
Nat Commun ; 11(1): 1677, 2020 04 03.
Article in English | MEDLINE | ID: mdl-32245952

ABSTRACT

Human stem cell-derived hepatocyte-like cells (HLCs) offer an attractive platform to study liver biology. Despite their numerous advantages, HLCs lack critical in vivo characteristics, including cell polarity. Here, we report a stem cell differentiation protocol that uses transwell filters to generate columnar polarized HLCs with clearly defined basolateral and apical membranes separated by tight junctions. We show that polarized HLCs secrete cargo directionally: Albumin, urea, and lipoproteins are secreted basolaterally, whereas bile acids are secreted apically. Further, we show that enterically transmitted hepatitis E virus (HEV) progeny particles are secreted basolaterally as quasi-enveloped particles and apically as naked virions, recapitulating essential steps of the natural infectious cycle in vivo. We also provide proof-of-concept that polarized HLCs can be used for pharmacokinetic and drug-drug interaction studies. This novel system provides a powerful tool to study hepatocyte biology, disease mechanisms, genetic variation, and drug metabolism in a more physiologically relevant setting.


Subject(s)
Cell Culture Techniques/methods , Cell Polarity , Hepatocytes/physiology , Induced Pluripotent Stem Cells/physiology , Antiviral Agents/pharmacology , Cell Differentiation , Cells, Cultured , Drug Evaluation, Preclinical/methods , Drug Interactions , Hepatitis A Virus, Human/physiology , Hepatitis E virus/physiology , Hepatocytes/ultrastructure , Hepatocytes/virology , Humans , Liver/cytology , Liver/metabolism , Membrane Transport Proteins/metabolism , Microscopy, Electron, Transmission , Proof of Concept Study , Virion/metabolism , Virus Release , Virus Replication
4.
Front Microbiol ; 10: 912, 2019.
Article in English | MEDLINE | ID: mdl-31130924

ABSTRACT

The search for novel anti-infectives is one of the most important challenges in natural product research, as diseases caused by bacteria, viruses, and fungi are influencing the human society all over the world. Natural compounds are a continuing source of novel anti-infectives. Accordingly, curcumin, has been used for centuries in Asian traditional medicine to treat various disorders. Numerous studies have shown that curcumin possesses a wide spectrum of biological and pharmacological properties, acting, for example, as anti-inflammatory, anti-angiogenic and anti-neoplastic, while no toxicity is associated with the compound. Recently, curcumin's antiviral and antibacterial activity was investigated, and it was shown to act against various important human pathogens like the influenza virus, hepatitis C virus, HIV and strains of Staphylococcus, Streptococcus, and Pseudomonas. Despite the potency, curcumin has not yet been approved as a therapeutic antiviral agent. This review summarizes the current knowledge and future perspectives of the antiviral, antibacterial, and antifungal effects of curcumin.

5.
Fitoterapia ; 134: 314-322, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30807789

ABSTRACT

Chemical analysis of extracts from cultures of the plant pathogenic fungus Cytospora sp. strain CCTU A309 collected in Iran led to the isolation of two previously unreported heptanedioic acid derivatives namely (2R,3S) 2-hydroxy-3-phenyl-4-oxoheptanedioic acid (1) and (2S,3S) 2-hydroxy-3-phenyl-4-oxoheptanedioic acid (2) as diastereomers, four previously undescribed prenylated p-terphenyl quinones 3-6 in addition to five known metabolites. Their structures were elucidated on the basis of extensive spectroscopic analysis and high-resolution mass spectrometry. For metabolites 1 and 2, the absolute configurations at C-2 were deduced from comparison of the 1H NMR difference of their (S)- and (R)-phenylglycine methyl ester derivatives while the relative configurations were tentatively assigned by a J-based analysis and confirmed by comparison of 13C chemical shifts to literature data. The isolated compounds were tested for their cytotoxic, antimicrobial (including biofilm inhibition), antiviral, and nematicidal activities. While only moderate antimicrobial effects were observed, the terphenyl quinone derivatives 3-6 and leucomelone (10) exhibited significant cytotoxicity against the mouse fibroblast L929 and cervix carcinoma KB-3-1 cell lines with IC50 values ranging from 2.4 to 26 µg/mL. Furthermore, metabolites 4-6 showed interesting antiviral activity against hepatitis C virus (HCV).


Subject(s)
Anti-Bacterial Agents/pharmacology , Antineoplastic Agents, Phytogenic/pharmacology , Antiviral Agents/pharmacology , Ascomycota/chemistry , Quinones/pharmacology , Terphenyl Compounds/pharmacology , Animals , Anti-Bacterial Agents/isolation & purification , Antineoplastic Agents, Phytogenic/isolation & purification , Antiviral Agents/isolation & purification , Cell Line, Tumor , Humans , Iran , Mice , Microbial Sensitivity Tests , Molecular Structure , Quinones/isolation & purification , Secondary Metabolism , Terphenyl Compounds/isolation & purification
6.
Antiviral Res ; 147: 19-28, 2017 11.
Article in English | MEDLINE | ID: mdl-28923507

ABSTRACT

Approximately 142 million people worldwide are infected with hepatitis C virus (HCV). Although potent direct acting antivirals are available, high costs limit access to treatment. Chronic hepatitis C virus infection remains a major cause of orthotopic liver transplantation. Moreover, re-infection of the graft occurs regularly. Antivirals derived from natural sources might be an alternative and cost-effective option to complement therapy regimens for global control of hepatitis C virus infection. We tested the antiviral properties of a mixture of different Chinese herbs/roots named Zhi Bai Di Huang Wan (ZBDHW) and its individual components on HCV. One of the ZBDHW components, Penta-O-Galloyl-Glucose (PGG), was further analyzed for its mode of action in vitro, its antiviral activity in primary human hepatocytes as well as for its bioavailability and hepatotoxicity in mice. ZBDHW, its component Cortex Moutan and the compound PGG efficiently block entry of HCV of all major genotypes and also of the related flavivirus Zika virus. PGG does not disrupt HCV virion integrity and acts primarily during virus attachment. PGG shows an additive effect when combined with the well characterized HCV inhibitor Daclatasvir. Analysis of bioavailability in mice revealed plasma levels above tissue culture IC50 after a single intraperitoneal injection. In conclusion, PGG is a pangenotypic HCV entry inhibitor with high bioavailability. The low cost and wide availability of this compound make it a promising candidate for HCV combination therapies, and also emerging human pathogenic flaviviruses like ZIKV.


Subject(s)
Antiviral Agents/pharmacology , Drugs, Chinese Herbal/chemistry , Hepacivirus/drug effects , Hydrolyzable Tannins/pharmacology , Paeonia/chemistry , Virus Attachment/drug effects , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacokinetics , Biological Availability , Carbamates , Cell Line, Tumor , Cells, Cultured , Drug Synergism , Drugs, Chinese Herbal/pharmacology , Hepacivirus/genetics , Hepacivirus/physiology , Hepatitis C/drug therapy , Hepatitis C, Chronic/drug therapy , Hepatocytes/drug effects , Humans , Hydrolyzable Tannins/administration & dosage , Hydrolyzable Tannins/pharmacokinetics , Imidazoles/pharmacology , Mice , Mice, SCID , Plant Extracts/chemistry , Plant Extracts/pharmacology , Pyrrolidines , Valine/analogs & derivatives , Virion/drug effects , Virus Replication/drug effects
7.
Virus Res ; 198: 9-14, 2015 Feb 16.
Article in English | MEDLINE | ID: mdl-25550074

ABSTRACT

Previous studies using lipid extracts of heather (Calluna vulgaris) leaves showed the presence of high concentrations of ursolic and oleanolic acid. These two compounds have been reported to present antiviral activity against hepatitis C virus (HCV). In this work, the supercritical fluid extraction of heather was studied with the aim of assessing a potential anti-HCV activity of the extracts owing to their triterpenic acid content. Supercritical extraction assays were carried out exploring the pressure range of 20-50 MPa, temperatures of 40-70°C and 0-15% of ethanol cosolvent. The content of oleanolic and ursolic acid in the extracts were determined, and different samples were screened for cellular cytotoxicity and virus inhibition using a HCV cell culture infection system. Antiviral activity was observed in most extracts. In general, superior anti-HCV activity was observed for higher contents of oleanolic and ursolic acids in the extracts.


Subject(s)
Antiviral Agents/pharmacology , Calluna/chemistry , Chromatography, Supercritical Fluid , Hepacivirus/drug effects , Plant Extracts/pharmacology , Antiviral Agents/isolation & purification , Antiviral Agents/toxicity , Cell Line , Cell Survival/drug effects , Hepatocytes/drug effects , Humans , Hydrostatic Pressure , Microbial Viability/drug effects , Oleanolic Acid/analysis , Plant Extracts/isolation & purification , Plant Extracts/toxicity , Temperature , Triterpenes/analysis , Ursolic Acid
8.
PLoS One ; 9(4): e92876, 2014.
Article in English | MEDLINE | ID: mdl-24690894

ABSTRACT

We investigated the in vitro and in vivo activities of epigallocatechin-3-gallate (EGCg), a green tea component, against Stenotrophomonas maltophilia (Sm) isolates from cystic fibrosis (CF) patients. In vitro effects of EGCg and the antibiotic colistin (COL) on growth inhibition, survival, and also against young and mature biofilms of S. maltophilia were determined. Qualitative and quantitative changes on the biofilms were assessed by confocal laser scanning microscopy (CLSM). Further, in vivo effects of nebulized EGCg in C57BL/6 and Cftr mutant mice during acute Sm lung infection were evaluated. Subinhibitory concentrations of EGCg significantly reduced not only biofilm formation, but also the quantity of viable cells in young and mature biofilms. CLSM showed that EGCg-exposed biofilms exhibited either a change in total biofilm biovolume or an increase of the fraction of dead cells contained within the biofilm in a dose depended manner. Sm infected wild-type and Cftr mutant mice treated with 1,024 mg/L EGCg by inhalation exhibited significantly lower bacterial counts than those undergoing no treatment or treated with COL. EGCg displayed promising inhibitory and anti-biofilm properties against CF Sm isolates in vitro and significantly reduced Sm bacterial counts in an acute infection model with wild type and CF mice. This natural compound may represent a novel therapeutic agent against Sm infection in CF.


Subject(s)
Biofilms/growth & development , Catechin/analogs & derivatives , Stenotrophomonas maltophilia/physiology , Tea/chemistry , Animals , Bacterial Load/drug effects , Biofilms/drug effects , Catechin/pharmacology , Colistin/pharmacology , Female , Instillation, Drug , Kinetics , Mice, Inbred C57BL , Mice, Mutant Strains , Microbial Sensitivity Tests , Stenotrophomonas maltophilia/drug effects , Stenotrophomonas maltophilia/isolation & purification
9.
Hepatology ; 54(6): 1947-55, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21837753

ABSTRACT

UNLABELLED: Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma. Current antiviral therapy fails to clear infection in a substantial proportion of cases. Drug development is focused on nonstructural proteins required for RNA replication. Individuals undergoing orthotopic liver transplantation face rapid, universal reinfection of the graft. Therefore, antiviral strategies targeting the early stages of infection are urgently needed for the prevention of HCV infection. In this study, we identified the polyphenol, epigallocatechin-3-gallate (EGCG), as an inhibitor of HCV entry. Green tea catechins, such as EGCG and its derivatives, epigallocatechin (EGC), epicatechin gallate (ECG), and epicatechin (EC), have been previously found to exert antiviral and antioncogenic properties. EGCG had no effect on HCV RNA replication, assembly, or release of progeny virions. However, it potently inhibited Cell-culture-derived HCV (HCVcc) entry into hepatoma cell lines as well as primary human hepatocytes. The effect was independent of the HCV genotype, and both infection of cells by extracellular virions and cell-to-cell spread were blocked. Pretreatment of cells with EGCG before HCV inoculation did not reduce HCV infection, whereas the application of EGCG during inoculation strongly inhibited HCV infectivity. Moreover, treatment with EGCG directly during inoculation strongly inhibited HCV infectivity. Expression levels of all known HCV (co-)receptors were unaltered by EGCG. Finally, we showed that EGCG inhibits viral attachment to the cell, thus disrupting the initial step of HCV cell entry. CONCLUSION: The green tea molecule, EGCG, potently inhibits HCV entry and could be part of an antiviral strategy aimed at the prevention of HCV reinfection after liver transplantation.


Subject(s)
Catechin/analogs & derivatives , Hepacivirus/drug effects , Hepatitis C/prevention & control , Virus Attachment/drug effects , Catechin/pharmacology , Cell Line, Tumor , Cells, Cultured , Hepacivirus/physiology , Humans , Tea/chemistry , Virus Internalization/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL